Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026)

Fortrea Holdings (FTRE) posted Liabilities and Shareholders Equity of $2.7 billion for Q1 2026, down 1.19% on a QoQ basis from $2.7 billion in Q4 2025, and down 14.02% year-over-year from $3.1 billion in Q1 2025.

Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

Fortrea Holdings' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 14.02% year-over-year to $2.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 billion (down 21.2% YoY) and the FY2025 annual result came in at $2.7 billion, down 24.13% from the prior year.
  • Liabilities and Shareholders Equity was $2.7 billion for Q1 2026 at Fortrea Holdings, down from $2.7 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $4.4 billion in Q2 2023 and bottomed at $2.7 billion in Q1 2026.
  • A 5-year average of $3.6 billion and a median of $3.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity climbed 1.04% — and 2025, when it slipped 26.39%.
  • Fortrea Holdings' Liabilities and Shareholders Equity stood at $4.3 billion in 2022, then increased by 1.04% to $4.3 billion in 2023, then retreated by 17.39% to $3.6 billion in 2024, then decreased by 24.13% to $2.7 billion in 2025, then declined by 1.19% to $2.7 billion in 2026.
  • Business Quant data shows FTRE's Liabilities and Shareholders Equity at $2.7 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.7 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Fortrea Holdings 1.83 Bn 1.68 Bn 123.60 Mn 2.68 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.68 Bn
Dec 31, 2025 2.72 Bn
Sep 30, 2025 2.74 Bn
Jun 30, 2025 2.84 Bn
Mar 31, 2025 3.12 Bn
Dec 31, 2024 3.58 Bn
Sep 30, 2024 3.66 Bn
Jun 30, 2024 3.57 Bn
Mar 31, 2024 4.24 Bn
Dec 31, 2023 4.33 Bn
Sep 30, 2023 4.32 Bn
Jun 30, 2023 4.36 Bn
Dec 31, 2022 4.29 Bn